Loomis Sayles & Co. L P Lowers Stake in Xencor, Inc. (NASDAQ:XNCR)

Loomis Sayles & Co. L P lessened its holdings in Xencor, Inc. (NASDAQ:XNCR) by 2.3% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 900,266 shares of the biopharmaceutical company’s stock after selling 20,918 shares during the quarter. Loomis Sayles & Co. L P owned about 1.29% of Xencor worth $18,104,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Primecap Management Co. CA grew its stake in shares of Xencor by 0.3% in the 2nd quarter. Primecap Management Co. CA now owns 9,116,202 shares of the biopharmaceutical company’s stock worth $172,570,000 after buying an additional 25,495 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Xencor by 3.6% during the first quarter. Vanguard Group Inc. now owns 7,011,042 shares of the biopharmaceutical company’s stock valued at $155,154,000 after acquiring an additional 243,793 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Xencor by 9.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,819,656 shares of the biopharmaceutical company’s stock worth $84,530,000 after purchasing an additional 335,881 shares during the last quarter. Logos Global Management LP boosted its stake in Xencor by 130.8% in the 2nd quarter. Logos Global Management LP now owns 1,500,000 shares of the biopharmaceutical company’s stock worth $28,395,000 after purchasing an additional 850,000 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its position in Xencor by 6.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,459,427 shares of the biopharmaceutical company’s stock valued at $27,628,000 after purchasing an additional 87,979 shares during the last quarter.

Insiders Place Their Bets

In other Xencor news, VP John R. Desjarlais sold 68,684 shares of the company’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $23.48, for a total value of $1,612,700.32. Following the completion of the sale, the vice president now owns 200,104 shares in the company, valued at $4,698,441.92. This represents a 25.55 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Bassil I. Dahiyat sold 49,278 shares of the firm’s stock in a transaction dated Thursday, November 21st. The stock was sold at an average price of $24.07, for a total value of $1,186,121.46. Following the completion of the transaction, the chief executive officer now directly owns 352,615 shares in the company, valued at $8,487,443.05. This trade represents a 12.26 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 121,328 shares of company stock worth $2,879,673. Company insiders own 5.23% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on XNCR. BMO Capital Markets reaffirmed an “outperform” rating and issued a $34.00 target price (up from $32.00) on shares of Xencor in a report on Friday, November 8th. Wedbush reaffirmed an “outperform” rating and issued a $38.00 price objective on shares of Xencor in a research report on Thursday, November 7th. JPMorgan Chase & Co. lifted their target price on Xencor from $27.00 to $28.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Finally, Royal Bank of Canada upped their price target on Xencor from $31.00 to $34.00 and gave the company an “outperform” rating in a report on Thursday, September 26th. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Xencor presently has an average rating of “Moderate Buy” and an average price target of $35.75.

Xencor Stock Performance

Xencor stock opened at $25.30 on Wednesday. Xencor, Inc. has a one year low of $15.31 and a one year high of $26.84. The stock has a fifty day moving average of $21.57 and a 200 day moving average of $20.39. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 0.01.

Xencor (NASDAQ:XNCR) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) EPS for the quarter, beating the consensus estimate of ($0.98) by $0.27. The firm had revenue of $10.70 million during the quarter, compared to analyst estimates of $14.59 million. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The business’s revenue for the quarter was down 81.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.40) EPS. Analysts forecast that Xencor, Inc. will post -3.71 EPS for the current fiscal year.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.